Bryan A. Supran serves as Executive Vice President, Chief Legal Officer, and Secretary at Alnylam Pharmaceuticals, Inc., a leading biopharmaceutical company pioneering RNA interference (RNAi) therapeutics. In this pivotal role, he oversees all legal, compliance, intellectual property, and corporate governance functions, guiding the company through complex regulatory landscapes, strategic partnerships, and global expansion. Supran plays a key part in Alnylam's mission to transform the lives of patients with rare and prevalent diseases, ensuring robust protection of groundbreaking innovations like the first FDA-approved RNAi drugs, including ONPATTRO®, GIVLAARI®, and OXLUMO®. Prior to joining Alnylam in 2013 as Vice President and General Counsel, Supran was a partner in the life sciences practice at WilmerHale, where he advised biotechnology and pharmaceutical clients on mergers and acquisitions, licensing agreements, and regulatory matters. His earlier career included roles as an associate at the same firm and clerkships that honed his expertise in high-stakes legal environments. A graduate of Harvard Law School (J.D.) and the University of Pennsylvania (B.A.), Supran has been instrumental in Alnylam's evolution from a research-stage company to a commercial leader, facilitating over $3 billion in collaborations and financings. Under Supran's leadership, Alnylam has strengthened its intellectual property portfolio, comprising thousands of patents, and navigated successful FDA approvals and international launches. His strategic counsel has supported key milestones, such as the company's Nasdaq debut and subsequent acquisitions, solidifying Alnylam's position at the forefront of gene silencing technology.